Immunotoxins

Bibliography

• GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA: Cancer Statistics, 2000, CA Cancer. J. Clin. (2000) 50:7–33.
   Google Scholar
• YAMAIZUMI M, MEKADA E, UCHIDA T, OKADA Y: One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell (1978) 15:245–250.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ: Getting plant toxins to fuse. Leukemia Res. (1997) 21:997–999.
   PubMed Web of Science ®Google Scholar
• •Review explaining why constructing fusion toxins is easier using bacterial toxins than plant toxins.
   Google Scholar
• GHETIE V, TILL MA, GHETIE MA, UHR JW, VITETTA ES:Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain. j Immunol Methods (1990) 126:135–141.
   PubMed Web of Science ®Google Scholar
• PAT LH, WITTES R, SETSER A, WILLINGHAM MC, PASTAN I: Treatment of advanced solid tumours with immuno-toxin 1MB-1: an antibody linked to Pseudomonas exotoxin. Nature Med. (1996) 2:350–353.
   PubMedGoogle Scholar
• ••Pai et al. describe the first clinical trial of an immunotoxincontaining truncated PE. The chemical conjugate LMB-1, containing the anti-Le Y mAb B3 and PE38, was tested in 38 patients with solid tumours. In this trial, the first major responses of colon and breast cancer to immunotoxins were observed. The DLT was due to VLS.
   Google Scholar
• GHETIE V, SWINDELL E, UHR JW, VITETTA ES: Purifica-tion and properties of immunotoxins containing one VS. two deglycosylated ricin A chains. J. Immunol. Methods (1993) 166:117–122.
   PubMed Web of Science ®Google Scholar
• STUDIER FW, MOFFATT BA: Use of bacteriophage 17 polymerase to direct selective expression of cloned genes. J. Mol Biol. (1986) 189:113–130.
   PubMed Web of Science ®Google Scholar
• BUCHNER J, PASTAN I, BRINKMANN U: A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem. (1992) 205:263–270.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, PASTAN I: Making fusion toxins to target leukemia and lymphoma. In: Drug Targeting. Francis GE, Delgado C (Eds.), Humana Press Inc., Totowa, NJ, USA (2000) 25:215–226.
   Google Scholar
• •Detailed protocol for production of recombinant fusion protein from inclusion bodies.
   Google Scholar
• KREITMAN RJ, PASTAN I: Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood (1997) 90:252–259.
   PubMed Web of Science ®Google Scholar
• LEMAISTRE CF, SALEH MN, KUZEL TM et al.: Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood (1998) 91:399–405.
   PubMed Web of Science ®Google Scholar
• ••Clinical results in patients tested with the recombinantsingle-chain IL-2-toxin DAB389IL2 (Figure 1). Major responses were seen in 13/35 patients with CTCL and 3/17 patients with NHL. The MTD was 27 p,g/kg/d x5 due to asthenia. Most of the CTCL patients showed significant improvement in skin lesions.
   Google Scholar
• RE GG, WATERS C, POISSON L, WILLINGHAM MC, SUGAMURA K, FRANKEL AE: Interleukin-2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB(389)IL-2 in cultured hematop o ie tic cells. Cancer Res. (1996) 56:2590–2595.
   PubMed Web of Science ®Google Scholar
• DUVIC M, KUZEL T, OLSEN E et al.: Quality of life is significantly improved in CTCL patients who responded to DAB389IL-2 (ONTAK) fusion protein. Blood (1998) 92 (Suppl. 1):2572a.
   Google Scholar
• BAGEL J, GARLAND WT, BRENEMAN D et al: Administra-tion of DAB(389)IL-2 to patients with recalcitrant psoriasis: A double-blind, Phase II multicenter trial. J. Am. Acad. Dermatol (1998) 38:938–944.
   PubMed Web of Science ®Google Scholar
• YAGURA H, TAMAKI T, FURITSU T et al: Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: functional and structural characterization. Blut. (1990) 60:181–186.
   PubMedGoogle Scholar
• CHAUDHARY VK, QUEEN C, JUNGHANS RP, WALDMANN TA, FITZGERALD DJ, PASTAN I: A recombin an t immun o-toxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 339:394–397.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, BAILON P, CHAUDHARY VK, FITZGERALDDJP, PASTAN I: Recombinant immunotoxins f Pseudomonas exotoxin produce complete regres-sion in mice of an interleukin-2 receptor-expressing human carcinoma. Blood (1994) 83:426–434.
   PubMed Web of Science ®Google Scholar
• •This study shows that the recombinant immunotoxin anti-Tac(Fv)-PE38 (later called LMB-2) induces CRs in mice bearing human CD25+ xenografts. Antitumour activity required both CD25-binding and ADP-ribosylation activities of the toxin, since mutants deficient in CD25-binding or ADP-ribosylation activity were inactive.
   Google Scholar
• KREITMAN RJ, PASTAN I: Targeting Pseudomonas ex otoxin to hematologic malignancies. Semin. Cancer. Biol. (1995) 6:297–306.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, PASTAN I: Accumulation of a recombi-nant immunotoxin in vivo: less than 1000 molecules per cell is sufficient for complete responses. Cancer Res. (1998) 58:968–975.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, WILSON WH, ROBBINS D et al: Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood (1999) 94:3340–3348.
   PubMed Web of Science ®Google Scholar
• ••A reported 100% response rate in 4 patients withchemotherapy refractory HCL to the recombinant single-chain immunotoxin LMB-2. This is the first report of major responses in cancer to any protein containing an Fv.
   Google Scholar
• KREITMAN RJ, WILSON WH, WHITE JD et al.: Phase I trialof recombinant immunotoxin Anti-Tac(Fv)-PE38 (IMB-2) in patients with hematologic malignancies. J. Clin. Oncol. (2000) 1 8 :1614–1636.
   Google Scholar
• MAVROUDIS DA, JIANG YZ, HENSEL N et al.: Specificdepletion of alloreactivity against haplotype mismatched related individuals: a new approach to graft-versus-host disease prophylaxis in haploiden-tical bone marrow transplantation. Bone Marrow Transplant. (1996) 17:793–799.
   PubMed Web of Science ®Google Scholar
• ENGERT A, DIEHL V, SCHNELL R et al: A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood (1997) 89:403–410.
   PubMed Web of Science ®Google Scholar
• ••2 out of 15 patients respond to the anti-CD25 immunotoxinchemical conjugate, that the DLT is due to VLS and that 7 of 15 patients produced antibodies. One of the patients had a very durable (> 2 year) remission.
   Google Scholar
• SCHNELL R, VITETTA E, SCHINDLER J et al.: Clinical trialswith an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leukemia & Lymphoma (1998) 30:525.
   PubMed Web of Science ®Google Scholar
• SCHNELL R, VITETTA E, SCHINDLER J et al: Treatment ofrefractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia (2000) 14:129–135.
   PubMed Web of Science ®Google Scholar
• MONTAGNA D, YVON E, CALCATERRA V et al.: Depletionof alloreactive T-cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood (1999) 93:3550–3557.
   PubMed Web of Science ®Google Scholar
• AMLOT PL, STONE MJ, CUNNINGHAM D eta].: A Phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 82:2624–2633.
   Google Scholar
• ••Report that RFB4-dgA induces major responses in patientswith B-cell malignancies, with dose limiting VLS.
   Google Scholar
• SAUSVILLE EA, HEADLEE D, STETLER-STEVENSON M et al.: Continuous infusion of the anti-CD22 immuno-toxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a Phase I study. Blood (1995) 85:3457–3465.
   PubMed Web of Science ®Google Scholar
• ••A phase I trial in which B-cell lymphoma and leukemiapatients received the anti-CD22 immunotoxin by continuous infusion. Compared to bolus dosing, the MTD was somewhat higher and both toxicity and efficacy were comparable.
   Google Scholar
• SENDEROWICZ AM, VITETTA E, HEADLEE D et al.: Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann. Intern. Med. (1997) 126:882–885.
   PubMed Web of Science ®Google Scholar
• STONE MJ, SAUSVILLE EA, FAY JW et al: A Phase I studyof bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood (1996) 88:1188–1197.
   PubMed Web of Science ®Google Scholar
• MESSMANN RA, VITETTA ES, HEADLEE D eta].: APhase Istudy of combination therapy with immunotoxins IgG-HD37- deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19 (+), CD22 (+) B-cell lymphoma. Clin. Cancer Res. (2000) 6:1302-1313. (In Process).
   Google Scholar
• KREITMAN RJ, WANG QC, FITZGERALD DJP, PASTAN I:Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant antiCD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus monkeys. Int. J. Cancer (1999) 81:148–155.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, MARGULIES I, STETLER-STEVENSON M, WANG QC, FITZGERALD DJP, PASTAN I: Cytotoxic activity of disulphide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias. Clin. Cancer Res. (2000) 6:1476–1487.
   PubMed Web of Science ®Google Scholar
• KUAN C, PAI LH, PASTAN I: Immun 0 toxins containingPseudomonas ex o tox in targeting IzY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin. Cancer Res. (1995) 1:1589–1594.
   PubMed Web of Science ®Google Scholar
• • Anti-Le' immunotoxins containing PE38 and dgA are cytotoxic to HUVECs and this may explain why these agents cause VLS. PE38 was not responsible for the cytotoxicity, since anti-Tac(Fv)-PE38 (LMB-2) was not cytotoxic and since the cytotoxicity of the B3-immunotoxins could be competed by B3 mAb.
   Google Scholar
• SOLER-RODRIGUEZ A-M, GHETIE M-A, OPPENHEIMER-MARKS N, UHR JW, VITETTA ES: Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: Implications for vascular leak syndrome. Exp. Cell Res. (1993) 206:227-234. Exp. Opin. Pharmacother. (2000) 1(6)
   Google Scholar
• PERENTESIS JP, GUNTHER R, WAURZYNIAK B et al: Invivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. an. Cancer Res. (1997) 3:2217–2227.
   Google Scholar
• KIM CN, BHALLA K, KREITMAN RJ et al.: Diphtheria toxinfused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leukemia Research (1999) 23:527–538.
   PubMed Web of Science ®Google Scholar
• UCKUN FM, BELLOMY K, ONEILL K, MESSINGER Y, JOHNSON T, CHEN CL: Toxicity, biological activity and pharmacokinetics of TXU (Anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. J. Pharmacol. Exp. Ther. (1999) 291:1301–1307.
   PubMed Web of Science ®Google Scholar
• ENGERT A, GOTTSTEIN C, BOHLEN H et al: Cocktails ofricin A-chain immuno toxins against different antigens on Hodgkin and Sternberg-Reed cells have superior antitumour effects against H-RS cells in vitro and solid Hodgkin tumours in mice. Int. J. Cancer (1995) 63 :304–309.
   PubMed Web of Science ®Google Scholar
• SCHNELL R, STAAK JO, SCHWARTZ C etal.: Clinical Phasetrial with a novel ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ lymphoma. Blood (1999) 94 :93a(407).
   Google Scholar
• JAIN RK: Delivery of molecular medicine to solidtumours. Science (1996) 271:1079–1080.
   PubMed Web of Science ®Google Scholar
• PASTAN I, LOVELACE ET, GALLO MG, RUTHERFORD AV,MAGNANI JL, WILLINGHAM MC: Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res. (1991) 51:3781–3787.
   PubMed Web of Science ®Google Scholar
• BRINKMANN U, PAI LH, FITZGERALD DJ, WILLINGHAM MPASTAN I: B3(Fv)-PE38KDEL, a single-chain immuno-toxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA. (1991) 88:8616–8620.
   PubMed Web of Science ®Google Scholar
• SIEGALL CB, CHACE D, MIXAN B et al.: In vitro and invivo characterization of BR96 sFv-PE40.A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats. J Immunol. (1994) 152:2377–2384.
   Google Scholar
• GREENFIELD L, JOHNSON VG, YOULE RJ: Mutations indiphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science (1987) 238:536–539.
   PubMed Web of Science ®Google Scholar
• PURI RK, LELAND P, KREITMAN RJ, PASTAN I: Humanneurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of 1L4-Pseudomonas exotoxin chimeric protein. Int. J. Cancer (1994) 58:574–581.
   PubMed Web of Science ®Google Scholar
• PURI RK, HOON DS, LELAND P et al.: Preclinical develop-ment of a recombinant toxin containing circularly permuted interleukin-4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res. (1996) 56:5631–5637.
   PubMed Web of Science ®Google Scholar
• •Describes the preclinical development of the circularly permuted IL-4-toxin(38–37)-PE38KDEL for the intratu-moural therapy of high-grade gliomas. Significant IL-4R expression was documented in a high proportion of gliomas but not in normal brain. Concentrations up to 1.3 1.1g/m1 in the CSF of monkeys and up to 100 jig/ml in the cerebral cortex of rats were non-toxic.
   Google Scholar
• KREITMAN RJ, PURI RK, PASTAN I: A circularly permutedrecombinant interleukin-4 toxin with increased activity. Proc. Nati Acad. Sci. USA (1994) 91:6889–6893.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, PURI RK, PASTAN I: Increased antitumouractivity of a circularly permuted interleukin-4-toxin in mice with interleukin-4 receptor-bearing human carcinoma. Cancer Res. (1995) 55:3357–3363.
   PubMed Web of Science ®Google Scholar
• HUSAIN SE, BEHARI N, KREITMAN RJ, PASTAN I, PURI RK:Complete regression of established human glioblas-toma tumour xenografts by interleukin-4 toxin therapy. Cancer Res. (1997) 58:3649–3653.
   Google Scholar
• RAND RW, KREITMAN RJ, PATRONAS N, VARRICCHIO F, PASTAN, I, PURI RK: Intratumoural administration of a recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high grade glioma. Clin. Cancer Res. (2000) 6:2157–2165.
   PubMed Web of Science ®Google Scholar
• ••Report of the effects of 1L4(38–37)-PE38KDEL as intratu-moural therapy in 9 patients with high-grade gliomas, including one durable CR.
   Google Scholar
• HUSAIN SR, PURI RK: Interleukin-13 receptor as a specific molecular target for cytotoxin therapy of human renal cell carcinoma in a xenograft model. Clin. Cancer Res. (1999) 5 (Suppl.) :3766s.
   Google Scholar
• PURI RK, LELAND P, OBIRI NI et al.: Targeting of Interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood (1996) 87:4333–4339.
   PubMed Web of Science ®Google Scholar
• GOLDBERG MR, HEIMBROOK DC, RUSSO P et al.: Phase Iclinical study of recombinant oncotoxin TP40 in superficial bladder cancer. Clin. Cancer Res. (1995) 1 :57–61.
   PubMed Web of Science ®Google Scholar
• CLARK DS, EMERY JM, MUNSELL MF: Inhibition ofposterior capsule opacification with an immunotoxin specific for lens epithelial cells: 24 month clinical results. J. Cataract Refract. Surg. (1998) 24:1614–1620.
   PubMedGoogle Scholar
• SIEGALL CB, HAGGERTY HG, WARNER GL et al.: Preven-tion of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumour efficacy. J. Immunol. (1997) 159:5168–5173.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN P, GRILLOLOPEZ AJ, LINK BK et al.:Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16:2825-2833. Exp. Opin. Pharmacother. (2000) 1(6)
   Google Scholar
• SIEGALL CB, LIGGITT D, CHACE D et al: Characteriza- tion of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with non-steroidal anti-inflammatory drugs. (1997) Clin. Cancer Res. 3: 339–345.
   Google Scholar
• ••Demonstrates that truncated PE alone is sufficient forinducing VLS in rats and that this requires proteolytic processing of the toxin as well as the ADP-ribosylation of elongation factor 2. VLS could be prevented by the non-steroidal anti-inflammatory agents indomethacin, piroxicam and flurbiprofen.
   Google Scholar
• SIEGALL CB, LIGGITT D, CHACE D, TEPPER MA, FELL HP:Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumour activity. Proc. Natl. Acad. Sci. USA (1994) 91:9514–9518.
   PubMed Web of Science ®Google Scholar
• ROZEMULLER H, ROMBOUTS WJC, TOUW IP et al: Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model. Leukemia (1996) 10: 1796-1803.
   Google Scholar
• KOBAYASHI H, HAN E, KIM I et al.: Similarities in thebiodistribution of iodine-labeled anti-Tac single-chain disulphide-stabilized Fv Fragment and an ti-Tac disulphide-stabilized Fv Fragment. Nucl. Med. Biol. (1998) 25:387–393.
   PubMed Web of Science ®Google Scholar
• DIVGI CR, SCOTT AM, DANTIS L et al: Phase I radioim-munotherapy trial with iodine-131 -CC49 in metastatic colon carcinoma. J. Nucl. Med. (1995) 36:586–592.
   PubMed Web of Science ®Google Scholar
• TOLCHER AW, SUGARMAN S, GELMON KA et al.: Randomized Phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. (1999) 17:478–484.
   PubMed Web of Science ®Google Scholar
• UCKUN FM, MESSINGER Y, CHEN CL et al.: Treatment oftherapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kin as e inhibitor. Clin. Cancer Res. (1999) 5:3906–3913.
   PubMed Web of Science ®Google Scholar
• SIEVERS EL, APPELBAUM FR, SPIELBERGER RT et al.:Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a Phase I study of an an ti-CD33 calicheamicin immun o conjugate. Blood (1999) 93:3678–3684.
   PubMed Web of Science ®Google Scholar
• FRANKEL AE, LAVER JH, WILLINGHAM MC, BURNS LJ, KERSEY JH, VALLERA DA: Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk. Lymphoma (1997) 26:287–298.
   PubMed Web of Science ®Google Scholar
• HALL PD, WILLINGHAM MC, KREITMAN RJ, FRANKEL AE:D1388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony stimulating factor, prolongs survival in a SCID model of acute myelogenous leukemia. Leukemia (1999) 13:629–633.
   PubMed Web of Science ®Google Scholar
• FOSS FM, SALEH MN, KRUEGER JG, NICHOLS JC, MURPHY JR: Diphtheria toxin fusion proteins. In: Clinical Applications of Immunotoxins. Frankel AE (Ed.), Springer-Verlag, Berlin, Germany (1998) :63–81.
   Google Scholar
• ••This review provides results of clinical trials of the IL-2-toxinDAB389IL2, including Phase III results which led to the approval by the FDA of this agent for persistent or recurrent CD25+ CTCL. Data from clinical testing of DAB389 EGF are also given.
   Google Scholar
• LASKE DW, YOULE RJ, OLDFIELD EH: Tumour regres-sion with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumours. Nature Medicine (1997) 3:1362–1368.
   PubMed Web of Science ®Google Scholar
• ••Patients treated with brain tumours intratumourally with achemical conjugate of transferrin and mutated DT viastereo-tactically placed catheters. Two CRs and seven PRs were observed in 15 evaluable patients. The MTD was 0.66 jig/ml, limited by peritumoural brain injury attributed to the uptake of the immunotoxin by TFR+ endothelial cells. Systemic toxicity was not dose-limiting despite the appearance of transient transaminase elevations.
   Google Scholar
• UCHIDA T, PAPPENHEIMER AM Jr, HARPER AA: Reconsti-tution of diphtheria toxin from two non-toxic cross-reacting mutant proteins. Science (1972) 175:901–903.
   PubMed Web of Science ®Google Scholar
• ROLF JM, GAUDIN HM, EIDELS L: Localization of the diphtheria toxin receptor-binding domain to the carboxyl-terminal Mr -6000 region of the toxin./ Biol. Chem. (1990) 265:7331–7337.
   PubMed Web of Science ®Google Scholar
• KAUL P, SILVERMAN J, SHEN WH et al.: Roles of Glu 349 and Asp 352 in membrane insertion and translocation by diphtheria toxin. Protein Science (1996) 5:687–692.
   PubMed Web of Science ®Google Scholar
• HWANG J, FITZGERALD DJ, ADHYA S, PASTAN I: Functional domains of Pseudomonas ex otoxin identi-fied by deletion analysis of the gene expressed in E. coif Cell (1987) 48:129–136.
   PubMed Web of Science ®Google Scholar
• ALLURED VS, COLLIER RJ, CARROLL SF, MCKAY DB: Structure of ex otoxin A of Pseudomonas aeruginosa at 3.0 Angstrom resolution. Proc. Natl. Acad. Sci. USA (1986) 83:1320–1324.
   PubMed Web of Science ®Google Scholar
• OGATA M, FRYLING CM, PASTAN I, FITZGERALD DJ: Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and G1y28° generates the enzymatically active fragment which translocates to the cytosol. Biol. Chem. (1992) 267:25396–25401.
   Web of Science ®Google Scholar